More differentiated information – supporting better treatment decisions

Lymph node status is one of the most important prognostic factors in many cancers and a key criterion for surgical and therapeutic decisions. Analysing lymph node tissue reliably and accurately is therefore crucial for detecting metastases.

Routine practice in histopathology analyses only a minimal amount of tissue and therefore provides only limited information, which might not reflect the real metastatic burden.

OSNA – One Step Nucleic Acid Amplification – is an automated molecular diagnostic assay that analyses the entire lymph node tissue. The reaction is based on rapid nucleic acid amplification technology (RT-LAMP*) to quantify Cytokeratin 19 (CK19) mRNA expression. CK19 is an epithelial cell marker and is normally not present in lymph node tissue. The expression rate of CK19 mRNA correlates with the size of the metastatic foci. 

The OSNA advantages

Excellent diagnostic information

• More accurate determination of the metastatic burden by analysing the entire lymph node
• Standardised, objective assessment of the lymph node status

Confidence

• Fast availability of results for optimal decision-making as to the right surgical/non-surgical approach
• Confident staging as reliable basis for choosing therapy

Patient quality of life

• Next therapy measures can start earlier
• Reduced waiting time and less patient stress

* RT-LAMP = Reverse transcriptase loop-mediated isothermal amplification; licensed under the agreement with Eiken Chemical CO., LTD